Symbol not found

NASDAQ:MDWD   00:00AM GMT
0.00
0.00 (0.00%)
Products

Mediwound Announces U.S. FDA Acceptance Of Biologics License Application For Nexobrid For Treatment Of Severe Thermal Burns

Published: 08/03/2022 12:13 GMT
MediWound Ltd (MDWD) - Mediwound Announces U.S. FDA Acceptance of Biologics License Application for Nexobrid for the Treatment of Severe Thermal Burns.
Mediwound Ltd - FDA Assigned a Prescription Drug User Fee Act (pdufa) Target Date of January 1, 2023.